YMAB - Y mAbs Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

YMAB is currently covered by 8 analysts with an average price target of $16.05. This is a potential upside of $7.44 (86.41%) from yesterday's end of day stock price of $8.61.

Y mAbs Therapeutics's activity chart (see below) currently has 87 price targets and 72 ratings on display. The stock rating distribution of YMAB is 68.75% BUY, 6.25% SELL and 25% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 42.25% with an average time for these price targets to be met of 101.5 days.

Highest price target for YMAB is $16, Lowest price target is $7, average price target is $11.52.

Most recent stock forecast was given by ROBERT BURNS from HC WAINWRIGHT on 06-Aug-2025. First documented stock forecast 16-Oct-2018.

Currently out of the existing stock ratings of YMAB, 11 are a BUY (68.75%), 1 are a SELL (6.25%), 4 are a HOLD (25%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold

$8.6

$-0.01 (-0.12%)

$11

3 months 28 days ago
(06-Aug-2025)

4/13 (30.77%)

$0.08 (0.94%)

144

Buy

$14

$5.39 (62.60%)

$18

6 months 20 days ago
(14-May-2025)

0/3 (0%)

$10.36 (284.62%)

Hold

$12

$3.39 (39.37%)

$10

8 months 29 days ago
(05-Mar-2025)

3/4 (75%)

$7.15 (147.42%)

114

Sell

$7

$-1.61 (-18.70%)

$11

9 months ago
(04-Mar-2025)

5/6 (83.33%)

$2.04 (41.13%)

180

Buy

$16

$7.39 (85.83%)

$17

9 months ago
(04-Mar-2025)

0/2 (0%)

$11.04 (222.58%)

Show more analysts

Please expand the browser size to see the chart

What is YMAB (Y mAbs Therapeutics) average time for price targets to be met?

On average it took 101.5 days on average for the stock forecasts to be realized with a an average price target met ratio 42.25

Which analyst has the current highest performing score on YMAB (Y mAbs Therapeutics) with a proven track record?

ETZER DAROUT

Which analyst has the most public recommendations on YMAB (Y mAbs Therapeutics)?

Etzer Darout works at BMO and has 12 price targets and 8 ratings on YMAB

Which analyst is the currently most bullish on YMAB (Y mAbs Therapeutics)?

Peter Lawson with highest potential upside - $56.39

Which analyst is the currently most reserved on YMAB (Y mAbs Therapeutics)?

Michael Ulz with lowest potential downside - -$1.61

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?